Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab.
Ustekinumab is approved for treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The Bmab 1200 autoinjector is a simple, two-step device for subcutaneous ustekinumab biosimilar delivery. This was an in vitro, nonclinical, simulated-use human fac…
Cardiovascular risk goal attainment in the United States rheumatologic population.
Rheumatologic diseases are independently linked to premature cardiovascular (CV) events. The emerging field of cardio-rheumatology addresses the intersection of inflammation and accelerated atherosclerosis driving excess CV risk. Despite calls to action, data on risk factor optimization, antihyperli…
Artificial Intelligence in Musculoskeletal Imaging: Innovations and Clinical Impact in Rheumatology.
This article summarizes key advancements of artificial intelligence (AI) for rheumatic and musculoskeletal disease imaging in the diagnosis and classification, and predictive modeling of rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, and osteoarthritis since 2020. AI applications are…
Targeting the Metabolic-Inflammatory Axis in Psoriasis and Psoriatic Arthritis: Evidence From Diet, Glucagon-like Peptide-1 Receptor Agonists, and Patient Perspectives.
Patients with psoriasis (PsO) and psoriatic arthritis (PsA) frequently present with obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome, all of which worsen outcomes and reduce treatment response. Dietary interventions represent one strategy to address this interplay, targeting the micr…
Harnessing Administrative Data for Real-World Evidence in Psoriatic Disease: Opportunities, Challenges, and Methodological Considerations.
Real-world data (RWD) from administrative claims and electronic health records provide a powerful resource for understanding treatment effectiveness, long-term safety, and the natural progression of disease. The promise of these data in psoriatic disease (PsD) was a topic for discussion at the Group…
Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting.
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 annual meeting was held from July 10 to 12, 2025, in Bogotá, Colombia. It was attended by 206 rheumatologists, dermatologists, trainees, patient research partners, representatives of patient organizations,…
Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes.
Dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used for type 2 diabetes, yet their comparative immunologic safety is uncertain. To address this gap, we evaluated autoimmune disease inc…